Product Reviews
Categories
- Alternative Medicine
- Cancer
- Acute Promyelocytic Leukemia
- Anal Cancer
- Bladder Cancer
- Breast cancer
- Colorectal cancer
- Endometrial Cancer
- Esophageal Cancer
- Gallbladder cancer
- Gastric Cancer
- Glioblastma
- Head and Neck Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Nasopharyngeal Cancer
- Non-Hodgkin's Disease
- Ovarian Cancer
- Pancreatic Cancer
- Prostate cancer
- Renal Cancer
- Thyroid Cancer
- Cardiovascular disease
- Central Nervous System
- Constipation
- Diabetes
- Fatty Liver
- Irritable Bowel Syndrome
- Longevity
- Motherhood
- Obesity
- Others
- Psoriasis
- Respiratory Disease
- Rheumatoid Arthritis
Archives
Tag Archives: Tarceva
New Monoclonal Antibodies Increased Survival in Lung Cancer Patients
A new study showed that non-small-cell lung cancer (NSCLC) patients who have high level of Met proteins in their tumor can have their survival increase three-fold by receiving experimental antibody MetMAb in combination with erlotinib (Tarceva). In the trial, 137 previously-treated … Continue reading
Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer
Tagged erlotinib, Met, MetMAb, Monoclonal antibodies, Non small cell lung cancer, NSCLC, progression-free survival, Survival, Tarceva
Comments Off on New Monoclonal Antibodies Increased Survival in Lung Cancer Patients
Afatinib Extend Time to Tumor Progression in Advanced Lung Cancer
Currently, no treatment exists for lung cancer patients with epidermal growth-factor receptor (EGFR) mutation who have failed tyrosine kinase inhibitors, getifinib (Iressa) or erlotinib (Tarceva). However, an investigational drug, afatinib (BIBW 2992), was recently found to increase progression-free survival and … Continue reading
Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer
Tagged Afatinib, epidermal growth-factor receptor, erlotinib, getifinib, Iressa, Lung Cancer, Non small cell lung cancer, NSCLC, platinum, progression-free survival, Tarceva, time to tumor progression, tumor shrinkage
Comments Off on Afatinib Extend Time to Tumor Progression in Advanced Lung Cancer
First-Line Erlotinib Triples Progression-Free Survival in NSCLC in Chinese Population
First-line erlotinib (Tarceva) tripled the progression-free survival in advanced non–small cell lung carcinoma (NSCLC) patients who had endothelial growth factor receptor (EGFR)-activating mutation, according to the OPTIMAL study presented at the 35th European Society for Medical Oncology Congress. The study … Continue reading
Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer
Tagged carboplatin, endothelial growth factor receptor, erlotinib, gemcitabine, Gemzar, non–small cell lung carcinoma, NSCLC, OPTIMAL, progression-free, Survival, Tarceva
Comments Off on First-Line Erlotinib Triples Progression-Free Survival in NSCLC in Chinese Population
Pancreatic cancer – Causes, Prevention, Prognosis, Diagnosis and Latest Treatment
Prevalence Pancreatic cancer is the fourth most common cause of adult cancer death, accounting for an estimated 42,470 new cases and 35,240 deaths in USA for 2009. The high mortality rate is due to the high incidence of metastatic disease … Continue reading
Posted in Pancreatic Cancer
Tagged Avastin, bevacizumab, capecitabine, Causes, Diagnosis, Eloxatin, erlotinib, gemcitabine, Gemzar, oxaliplatin, Pancreatic Cancer, Prevention, Prognosis, Survival, Tarceva, Treatment, Xeloda
2 Comments
